Table 3. Mean log IgG titer, in antibody units (U/ml), and 95% CI among the cancer cohort and healthy cohort by vaccine type.
1TP1: pre-first dose, TP2: pre-second dose, TP3: 2 weeks post-second dose, TP4: 6 months post-first dose.
| Time point1 | Cancer patients, antibody units (95% confidence interval) | Healthy individuals, antibody units (95% confidence interval) | |||
| BNT162b2 | AZ1222 | Coronavac | BNT162b2 | Coronavac | |
| TP1 | -0.18 (-0.39; 0.04) | 2.31 (0.77; 3.86) | -0.18 (-2.08; 1.72) | -0.56 (-0.78; -0.34) | -0.80 (-0.96; -0.64) |
| TP2 | 2.78 (2.47; 3.09) | 4.37 (3.33; 5.42) | -0.37 (-1.29; 0.54) | 4.36 (4.11; 4.61) | 1.07 (0.85; 1.29) |
| TP3 | 6.25 (5.98; 6.51) | 7.19 (6.56; 7.82) | 1.83 (0.27; 3.40) | 7.33 (7.13; 7.52) | 4.03 (3.74; 4.33) |
| TP4 | 7.07 (6.73; 7.40) | 6.08 (5.37; 6.78) | 5.87 (2.41; 9.34) | 8.54 (8.14; 8.95) | 6.38 (6.06; 6.70) |